Implementation of an Asthma Program to Improve Asthma Identification and Education in Children

This study has been completed.
Sponsor:
Collaborator:
Pennsylvania Department of Health
Information provided by (Responsible Party):
Duquesne University
ClinicalTrials.gov Identifier:
NCT01692080
First received: August 7, 2012
Last updated: August 5, 2013
Last verified: August 2013
  Purpose

The primary objective of this study is to document the prevalence and associations between asthma, hypertension, and obesity in children living in Pittsburgh, Pennsylvania and its surrounding regions.

The secondary objective is to determine the impact of various educational interventions on child and caregiver knowledge of asthma.


Condition Intervention
Asthma
Hypertension
Obesity
Behavioral: Asthma education

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Implementation of an Asthma Program to Improve Asthma Identification and Education in Children

Resource links provided by NLM:


Further study details as provided by Duquesne University:

Primary Outcome Measures:
  • The primary outcome of this study is to document the prevalence of asthma, hypertension and obesity in children living in Pittsburgh's inner-city. [ Time Frame: Up to three years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The secondary outcome of this study is to determine the impact of various educational interventions on child and caregiver knowledge of asthma. [ Time Frame: up to three years ] [ Designated as safety issue: No ]
    A pre and post asthma knowledge test will be given to children and caregivers prior to and after participation in the educational session conducted at each asthma camp. A paired sample t-test was used for comparison of pre and post knowledge tests and a p value of less than 0.05 will be considered to indicate a statistically significant difference.


Enrollment: 231
Study Start Date: January 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Asthma Screenings and Camps
Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
Behavioral: Asthma education
Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
Other Name: asthma knowledge intervention

Detailed Description:

The Asthma Program will consist of six screenings and three camps each year, for two consecutive years. Screenings will be conducted in areas where populations are known to be at increased risk for asthma and its complications, such as inner-city, lower socioeconomic, African-American populations. Screenings will be conducted at churches or schools in these areas one month prior to each camp in an effort to identify children with undiagnosed or uncontrolled asthma and refer them to the camps. Camps will also be conducted in areas where populations are known to be at increased risk for asthma and its complications to improve ease of access. Asthma and smoking cessation education will be provided at each camp to children and caregivers. Baseline data will be collected at each camp and assessed. Longitudinal clinical outcomes will be assessed in children attending multiple camps.

  Eligibility

Ages Eligible for Study:   5 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Two screenings will be held prior to each camp, at two separate locations, for a total of six screenings per year. Screenings will be held at different locations throughout the city of Pittsburgh in an effort to increase identification and recruitment for subsequent camps. All children will be invited to participate in screenings, regardless of participation in the study. All children, ages 5-17 years, will be included in our study pending informed consent and assent. Camps will take place three times each year. All children will be invited to participate in camps, regardless of participation in the study. All children, ages 5-17 years will be included in our study pending informed consent and assent.

Criteria

Inclusion Criteria:

  • Children, ages 5- 17 years attending the asthma camps and screenings.

Exclusion Criteria:

  • Children younger than 5 years of age and adults 18 years of age and older.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01692080

Locations
United States, Pennsylvania
Duquesne University
Pittsburgh, Pennsylvania, United States, 15282
Sponsors and Collaborators
Duquesne University
Pennsylvania Department of Health
Investigators
Principal Investigator: Jennifer P Elliott, PharmD Duquesne University
  More Information

No publications provided

Responsible Party: Duquesne University
ClinicalTrials.gov Identifier: NCT01692080     History of Changes
Other Study ID Numbers: DU Protocol #10-11
Study First Received: August 7, 2012
Last Updated: August 5, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Hypertension
Bronchial Diseases
Cardiovascular Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 20, 2014